Unione Europea - italiano - EMA (European Medicines Agency)

medimmune llc - reassortant virus dell'influenza (vivo attenuato) dei seguenti ceppi:a/california/7/2009 (h1n1)pdm09 come il ceppo a/victoria/361/2011 (h3n2) ceppo b/massachusetts/2/2012 ceppo - influenza, human; immunization - vaccini - profilassi dell'influenza negli individui da 24 mesi a meno di 18 anni. l'uso di fluenz dovrebbe essere basata sulle raccomandazioni ufficiali.

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

mylan pharma gmbh - haemagglutininum influenzae di tipo a (h1n1) (virus-stamm a/brisbane/02/2018 (h1n1)-like: reassortant virus a/brisbane/02/2018, ivr-190), haemagglutininum influenzae a (h3n2) (virus-stamm a/kansas/14/2017 (h3n2)-come: reassortant virus a/kansas/14/2017, nymc x-327), haemagglutininum influenzae b (virus stamm b/colorado/06/2017-come: reassortant virus b/veneto/15/2016 nymc bx-69a) - sospensione iniettabile - haemagglutininum influenzae a (h1n1) (virus-stamm a/brisbane/02/2018 (h1n1)-like: reassortant virus a/brisbane/02/2018, ivr-190) 15 µg, haemagglutininum influenzae a (h3n2) (virus-stamm a/kansas/14/2017 (h3n2)-like: reassortant virus a/kansas/14/2017, nymc x-327) 15 µg, haemagglutininum influenzae b (virus stamm b/colorado/06/2017-like: reassortant virus b/maryland/15/2016 nymc bx-69a) 15 µg, kalii chloridum, kalii dihydrogenophosphas, dinatrii phosphas dihydricus, natrii chloridum, calcii chloridum dihydricum, magnesii chloridum hexahydricum, residui: natrii citras dihydricus max. 1 mg, cetrimidum max. 15 µg, formaldehydum max. 10 µg, gentamicini sulfas max. 1 ng, tylosini tartras nihil, hydrocortisonum nihil, polysorbatum 80 nihil, ovalbuminum max. 0.1 µg, aqua ad iniectabile q.s. ad suspensionem pro 0.5 ml. - immunizzazione attiva contro l'influenza, che abbiano compiuto il 6. mese di vita - vaccini

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

glaxosmithkline ag - haemagglutininum influenzae di tipo a (h1n1) (virus stamm a/brisbane/02/2018 (h1n1)-like: reassortant virus ivr-190 derivato da a/brisbane/02/2018), haemagglutininum influenzae a (h3n2) (virus stamm a/kansas/14/2017 (h3n2)-come: reassortant virus nymc x-327 derivato da a/kansas/14/0217), haemagglutininum influenzae b (virus stamm b/colorado/06/2017-come: reassortant virus b/veneto/15/2016 nymc bx-69a (victoria lignaggio)) - sospensione iniettabile - haemagglutininum influenzae di tipo a (h1n1) (virus stamm a/brisbane/02/2018 (h1n1)-like: reassortant virus ivr-190 derivato da a/brisbane/02/2018) 15 µg, haemagglutininum influenzae a (h3n2) (virus stamm a/kansas/14/2017 (h3n2)-come: reassortant virus nymc x-327 derivato da a/kansas/14/0217) 15 µg, haemagglutininum influenzae b (virus stamm b/colorado/06/2017-come: reassortant virus (b/veneto/15/2016 nymc bx-69a (victoria lignaggio)) 15 µg, haemagglutininum influenzae b (virus stamm b/phuket/3073/2013 (yamagata lignaggio)) 15 µg, polysorbatum 80, octoxinolum-10, natrii chloridum, magnesio chloridum hexahydricum, dinatrii phosphas dodecahydricus, kalii dihydrogenophosphas, kalii chloridum, alfa-tocopheroli hydrogenosuccinas, il resto: ovalbuminum max. 0,05 µg, formaldehydum max. 5 µg, natrii desoxycholas max. 65 µg, gentamicini sulfas nulla, hydrocortisonum nulla, l'acqua ad iniectabilia q.s. la sospensione 0,5 ml. - immunizzazione attiva contro l'influenza, a partire da 36 mesi - vaccini

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

sanofi-aventis (suisse) sa - haemagglutininum influenzae di tipo a (h1n1) (virus souche a/brisbane/02/2018 / h1n1-pdm09: reassortant virus ivr-190 derivato da a/brisbane/02/2018), haemagglutininum influenzae a (h3n2) (virus souche un/kansas/14/2007 (h3n2)-come: reassortant virus nymc x-327 derivato da a/kansas/14/2017), haemagglutininum influenzae b (virus souche b/colorado/06/2017 (victoria lignaggio), ad esempio: reassortant virus nymc bx-69a derivata da b/veneto/15/2016) - sospensione iniettabile in siringa pre-riempita - haemagglutininum influenzae di tipo a (h1n1) (virus souche a/brisbane/02/2018 / h1n1-pdm09: reassortant virus ivr-190 derivato da a/brisbane/02/2018) 15 µg, haemagglutininum influenzae a (h3n2) (virus souche un/kansas/14/2007 (h3n2)-come: reassortant virus nymc x-327 derivato da a/kansas/14/2017) 15 µg, haemagglutininum influenzae b (virus souche b/colorado/06/2017 (victoria lignaggio)-come: reassortant virus nymc bx-69a derivata da b/veneto/15/2016) 15 µg, haemagglutininum influenzae b (virus souche b/phuket/3073/2013 (yamagata lignaggio)) 15 µg, natrii chloridum, kalii chloridum, dinatrii phosphas dihydricus, kalii dihydrogenophosphas, acqua ad iniectabilia q.s. la sospensione 0,5 ml, il resto: formaldehydum, octoxinolum-9, neomycinum, ovalbuminum. - immunizzazione attiva contro l'influenza, come già nel 6 ° mese - vaccini

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

mylan pharma gmbh - haemagglutininum influenzae di tipo a (h1n1) (virus-stamm a/brisbane/02/2018 (h1n1)-like: reassortant virus a/brisbane/02/2018, ivr-190), haemagglutininum influenzae a (h3n2) (virus-stamm a/kansas/14/2017 (h3n2)-come: reassortant virus a/kansas/14/2017, nymc x-327), haemagglutininum influenzae b (virus stamm b/colorado/06/2017-come: reassortant virus b/veneto/15/2016 nymc bx-69a) - sospensione iniettabile - haemagglutininum influenzae a (h1n1) (virus-stamm a/brisbane/02/2018 (h1n1)-like: reassortant virus a/brisbane/02/2018, ivr-190) 15 µg, haemagglutininum influenzae a (h3n2) (virus-stamm a/kansas/14/2017 (h3n2)-like: reassortant virus a/kansas/14/2017, nymc x-327) 15 µg, haemagglutininum influenzae b (virus stamm b/colorado/06/2017-like: reassortant virus b/maryland/15/2016 nymc bx-69a) 15 µg, kalii chloridum, kalii dihydrogenophosphas, dinatrii phosphas dihydricus, natrii chloridum, calcii chloridum dihydricum, magnesii chloridum hexahydricum, residui: natrii citras dihydricus max. 1 mg, cetrimidum max. 15 µg, formaldehydum max. 10 µg, gentamicini sulfas max. 1 ng, tylosini tartras nihil, hydrocortisonum nihil, polysorbatum 80 nihil, ovalbuminum max. 0.1 µg, aqua ad iniectabile q.s. ad suspensionem pro 0.5 ml. - immunizzazione attiva contro l'influenza, che abbiano compiuto il 6. mese di vita - vaccini

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

glaxosmithkline ag - haemagglutininum influenzae a (h1n1) (virus stamm a/guangdong-maonan/swl1536/2019 (h1n1)-like: reassortant virus cnic-1909 derived from a/guangdong-maonan/swl1536/2019), haemagglutininum influenzae a (h3n2) (virus stamm a/hong kong/2671/2019 (h3n2)-like: reassortant virus nib-121 derived from a/hong kong/2671/2019), haemagglutininum influenzae b (virus stamm b/washington/02/2019-like: reassortant virus b/washington/02/2019 (victoria lineage)) - sospensione iniettabile - haemagglutininum influenzae a (h1n1) (virus stamm a/guangdong-maonan/swl1536/2019 (h1n1)-like: reassortant virus cnic-1909 derived from a/guangdong-maonan/swl1536/2019) 15 µg, haemagglutininum influenzae a (h3n2) (virus stamm a/hong kong/2671/2019 (h3n2)-like: reassortant virus nib-121 derived from a/hong kong/2671/2019) 15 µg, haemagglutininum influenzae b (virus stamm b/washington/02/2019-like: reassortant virus b/washington/02/2019 (victoria lineage)) 15 µg, haemagglutininum influenzae b (virus stamm b/phuket/3073/2013 (yamagata lineage)) 15 µg, polysorbatum 80, octoxinolum-10, natrii chloridum, magnesii chloridum hexahydricum, dinatrii phosphas dodecahydricus, kalii dihydrogenophosphas, kalii chloridum, alpha-tocopheroli hydrogenosuccinas, aqua ad iniectabilia q.s. ad suspensionem pro 0.5 ml, residui: ovalbuminum, formaldehydum, natrii desoxycholas, gentamicini sulfas, hydrocortisonum. - immunizzazione attiva contro l'influenza, a partire da 36 mesi - vaccini

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

sanofi-aventis (suisse) sa - haemagglutininum influenzae a (h1n1) (virus souche a/michigan/45/2015 (h1n1)-like: reassortant virus nymc x-275 derived from a/michigan/45/2015), haemagglutininum influenzae a (h3n2) (virus souche a/singapore/infimh-16-0019/2016 (h3n2)-like: reassortant virus ivr-186 derived from a/singapore/infimh-16-0019/2016 ), haemagglutininum influenzae b (virus souche b/colorado/06/2017-like: reassortant virus nymc bx-69a derived from b/maryland/15/2016 (victoria lineage)) - suspension injectable en seringue préremplie - haemagglutininum influenzae a (h1n1) (virus souche a/michigan/45/2015 (h1n1)-like: reassortant virus nymc x-275 derived from a/michigan/45/2015) 60 µg, haemagglutininum influenzae a (h3n2) (virus souche a/singapore/infimh-16-0019/2016 (h3n2)-like: reassortant virus ivr-186 derived from a/singapore/infimh-16-0019/2016 ) 60 µg, haemagglutininum influenzae b (virus souche b/phuket/3073/2013 (yamagata lineage) (wild type)) 60 µg, haemagglutininum influenzae b (virus souche b/colorado/06/2017-like: reassortant virus nymc bx-69a derived from b/maryland/15/2016 (victoria lineage)) 60 µg, natrii chloridum, dinatrii phosphas, natrii dihydrogenophosphas anhydricus, octoxinolum-9, aqua ad iniectabile q.s. ad suspensionem pro 0.7 ml corresp. natrium 2.72 mg. - immunisation active contre l'influenza, dès 65 ans - vaccini

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

glaxosmithkline ag - haemagglutininum influenzae a (h1n1) (virus stamm a/victoria/2570/2019 (h1n1)-like: reassortant virus ivr-215 derived from a/victoria/2570/2019), haemagglutininum influenzae a (h3n2) (virus stamm a/cambodia/e0826360/2020 (h3n2)-like: reassortant virus ivr-221 derived from a/tasmania/503/2020), haemagglutininum influenzae b (virus stamm b/washington/02/2019-like: reassortant virus b/washington/02/2019 (victoria lineage)) - sospensione iniettabile - haemagglutininum influenzae a (h1n1) (virus stamm a/victoria/2570/2019 (h1n1)-like: reassortant virus ivr-215 derived from a/victoria/2570/2019) 15 µg, haemagglutininum influenzae a (h3n2) (virus stamm a/cambodia/e0826360/2020 (h3n2)-like: reassortant virus ivr-221 derived from a/tasmania/503/2020) 15 µg, haemagglutininum influenzae b (virus stamm b/washington/02/2019-like: reassortant virus b/washington/02/2019 (victoria lineage)) 15 µg, haemagglutininum influenzae b (virus stamm b/phuket/3073/2013 (yamagata lineage)) 15 µg, polysorbatum 80, octoxinolum-10, natrii chloridum, magnesii chloridum hexahydricum, dinatrii phosphas dodecahydricus, kalii dihydrogenophosphas, kalii chloridum, alpha-tocopheroli hydrogenosuccinas, aqua ad iniectabile q.s. ad suspensionem pro 0.5 ml, residui: ovalbuminum, formaldehydum, natrii desoxycholas, gentamicini sulfas, hydrocortisonum. - immunizzazione attiva contro l'influenza, a partire da 36 mesi - vaccini

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

sanofi-aventis (suisse) sa - haemagglutininum influenzae a (h1n1) (rha) (virus souche a/michigan/45/2015)-like: reassortant virus nymc x-275 derived from a/michigan/45/2015), haemagglutininum influenzae a (h3n2) (rha) (virus souche a/singapore/infimh-16-0019/2016)-like: reassortant virus ivr-186 derived form a/singapore/infimh-16-0019/2016), haemagglutininum influenzae b (rha) (virus souche b/phuket/3073/2013-like: reassortant virus b/phuket/3073/2013 (yamagata lineage)) - solution injectable dans une seringue pré-remplie - haemagglutininum influenzae a (h1n1) (adnr) (virus souche a/michigan/45/2015)-like: reassortant virus nymc x-275 derived from a/michigan/45/2015) 45 µg, haemagglutininum influenzae a (h3n2) (adnr) (virus souche a/singapore/infimh-16-0019/2016)-like: reassortant virus ivr-186 derived form a/singapore/infimh-16-0019/2016) 45 µg, haemagglutininum influenzae b (adnr) (virus souche b/phuket/3073/2013-like: reassortant virus b/phuket/3073/2013 (yamagata lineage)) 45 µg, haemagglutininum influenzae b (adnr) (virus souche b/colorado/6/2017-like: reassortant virus nymc bx-69a derived from b/maryland/15/2016 (victoria lineage)) 45 µg, natrii dihydrogenophosphas monohydricus, dinatrii phosphas dodecahydricus, natrii chloridum, polysorbatum 20, aqua ad iniectabile q.s. ad solutionem pro 0.5 ml corresp. natrium 1.84 mg, residui: octoxinolum-9. - immunisation active contre l'influenza, dès 18 ans - vaccini

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

glaxosmithkline ag - haemagglutininum influenzae a (h1n1) (virus stamm a/victoria/2570/2019 (h1n1)pdm09-like: reassortant virus ivr-215 derived from a/victoria/2570/2019), haemagglutininum influenzae a (h3n2) (virus stamm a/darwin/9/2021 (h3n2)-like: reassortant virus ivr-227 derived from a/darwin/6/2021), haemagglutininum influenzae b (virus stamm b/austria/1359417/2021-like: reassortant virus bvr-26 derived from b/austria/1359417/2021 (victoria lineage)) - sospensione iniettabile - haemagglutininum influenzae a (h1n1) (virus stamm a/victoria/2570/2019 (h1n1)pdm09-like: reassortant virus ivr-215 derived from a/victoria/2570/2019) 15 µg, haemagglutininum influenzae a (h3n2) (virus stamm a/darwin/9/2021 (h3n2)-like: reassortant virus ivr-227 derived from a/darwin/6/2021) 15 µg, haemagglutininum influenzae b (virus stamm b/austria/1359417/2021-like: reassortant virus bvr-26 derived from b/austria/1359417/2021 (victoria lineage)) 15 µg, haemagglutininum influenzae b (virus stamm b/phuket/3073/2013-like: b/phuket/3073/2013 wild type (yamagata lineage)) 15 µg, polysorbatum 80, octoxinolum-10, natrii chloridum, magnesii chloridum hexahydricum, dinatrii phosphas dodecahydricus, kalii dihydrogenophosphas, kalii chloridum, alpha-tocopheroli hydrogenosuccinas, aqua ad iniectabile q.s. ad suspensionem pro 0.5 ml, residui: ovalbuminum, formaldehydum, natrii desoxycholas, gentamicini sulfas, hydrocortisonum. - immunizzazione attiva contro l'influenza, a partire da 36 mesi - vaccini